WUSTL spinout Wugen has collected $172m in a series B round to progress its pipeline targeting several cancer indications.

The gene editing technology developer is the latest spinout emerging out of the lab of David Liu at Broad Institute.

Patient Square Capital has led a series B round for the Stanford-linked gene therapy developer, which previously collected $80.5m in May last year.

Bow Capital has helped supply fresh funding for the equity-free capital provider to boost its expansion and broaden its product offering.

Technion-linked cultured meat developer has raised a series B round that took its overall funding to $118m.

Umoja Biopharma, based on research at Purdue University and Seattle Children’s Research Institute, has picked up a series B co-led by SoftBank Vision Fund 2.

Motif FoodWorks, which traces its roots to MIT, has pocketed $226m in a round backed by returning investor Louis Dreyfus a month after Motif’s parent agreed to a reverse merger.

UCL Technology Fund has participated in a $145m round that will allow Apollo Therapeutics to advance assets into the clinic and open a US office.

The immuno-oncology therapy developer has amassed at least $190m of overall funding since emerging out of Stanford University.

Tencent has led a series E round that reportedly tripled LMU Munich-linked Scalable Capital's valuation to $1.4bn.